Menu
Search
|

Menu

Close
X

Erytech Pharma SA ERYP.OQ (NASDAQ Stock Exchange Global Select Market)

6.95 USD
-- (--)
As of Jul 18
Previous Close 6.95
Open --
Volume --
3m Avg Volume 931
Today’s High --
Today’s Low --
52 Week High 11.89
52 Week Low 5.54
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.10
Price to Sales (TTM)
vs sector
--
7.99
Price to Book (MRQ)
vs sector
--
4.39
Price to Cash Flow (TTM)
vs sector
--
24.00
Total Debt to Equity (MRQ)
vs sector
--
17.94
LT Debt to Equity (MRQ)
vs sector
--
12.82
Return on Investment (TTM)
vs sector
--
12.64
Return on Equity (TTM)
vs sector
--
17.18

EXECUTIVE LEADERSHIP

Jean-Paul Kress
Chairman of the Board, Since 2019
Salary: --
Bonus: --
Gil Beyen
Chief Executive Officer, Director, Since 2019
Salary: €345,000.00
Bonus: €138,000.00
Jerome Bailly
Deputy Chief Executive Officer - Chief Pharmacist, Since 2011
Salary: €168,024.00
Bonus: €38,400.00
Eric Soyer
Chief Financial Officer, Chief Operating Officer, Since 2015
Salary: --
Bonus: --
Alexander Scheer
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Batiment Adenine 60 avenue Rocke
LYON     69008

Phone: +334.78744438
Site: erytech.com/

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.

SPONSORED STORIES